BOSTON, Mass. – May 24, 2016 – BioPharm Insight, the most comprehensive life science market intelligence and analytics solution, recently released an exclusive preconference report for the American Society of Clinical Oncology (ASCO) 2016 meeting. The report is a must-read for everyone interested in oncology as it highlights key presentations to be made at ASCO, as well as, this publication’s coverage on the studies.
Get the full report: http://www.biopharminsight.com/asco-2016-preconference-report
Single-agent checkpoint inhibitors will continue to be among the hottest frontiers in cancer. Merck and Bristol-Myers Squibb (BMS) are presenting non-small-cell lung cancer (NSCLC) data to advance its respective PD-1 inhibitors to earlier lines of treatment. BioPharm Insight reports prospects of exceeding frontline platinum based chemotherapy in NSCLC will depend on Phase III patient selection intricacies. The report also includes breaking news on BMS’ and Merck’s strategies to position their immunotherapies versus chemotherapy as well as Merck’s progress in its ongoing Phase III NSCLC study.
Combination checkpoint inhibitors will also be addressed. BMS will be presenting Opdivo/Yervoy data in several tumor types including small-cell lung cancer (SCLC; Abstract #100). The combo has experts excited about its clinical potential in SCLC but also cautious as toxicity still remains a major concern, according to BioPharm Insight’s coverage. In colorectal cancer (Abstract #3501), the combo data will be watched closely, especially since single-agent data failed to impress. Additionally, underwhelming ovarian cancer data for monotherapy checkpoint inhibitors has driven interest in combination studies.
The preconference report shortlists 34 abstracts across 18 indications as highly important. Alongside the key abstracts are 24 BioPharm Insight articles based on interviews with Key Opinion Leaders. In addition to the aforementioned checkpoint inhibitors, read the report to get forward-looking analyses on several other immune-oncology treatments, targeted therapies and hematological cancer drugs that will be showcased at ASCO. Get the full report: http://www.biopharminsight.com/asco-2016-preconference-report
About BioPharm Insight
BioPharm Insight is the most comprehensive life science market intelligence and analytics solution, featuring a team of investigative journalists writing exclusive news and thousands of healthcare data points, aggregated into one centralized source. In addition to the proprietary articles, BioPharm Insight is currently tracking 710,000 management and R&D contacts, 7,500 biopharma companies with full pipeline data, 120,000 investigational and approved drug profiles, 28,000 M&A and licensing deals, 10,000 extended sales forecasts and epidemiology profiles for hundreds of indications. Meet with BioPharm Insight in person at BIO June 6-9 in San Francisco and DIA June 25-29 in Philadelphia. Learn more at http://www.biopharminsight.com